Market Place
Sourcing Support
FDA Confirms Paragraph IV Patent Litigation for Fedratinib Hydrochloride
21 Sep 2023 //
FDA
NICE recommends Inrebic for rare blood cancer
19 Nov 2021 //
PHARMATIMES
BMS`s Receives Positive CHMP Opinion for Inrebic® (fedratinib)
11 Dec 2020 //
BUSINESSWIRE
Bristol Myers Squibb Receives Positive CHMP Opinion for Inrebic® (fedratinib)
11 Dec 2020 //
BUSINESSWIRE
Health Canada Approves INREBIC® (fedratinib), First New Treatment in Nearly
21 Sep 2020 //
BIOSPACE
Celgene`s Reblozyl faces FDA committee for myelodysplastic syndromes
03 Dec 2019 //
FIERCE PHARMA
FDA Action Alert: Celgene, Xeris and Ardelyx
04 Sep 2019 //
BIOSPACE
First bone marrow disorder treatment approved by the FDA after nearly a decade
21 Aug 2019 //
IN-PHARMATECHNOLOGIST
FDA approves novel device to treat idiopathic scoliosis
19 Aug 2019 //
BIOSPECTRUMASIA
Celgene`s v Inrebic receives USFDA approval to treat patients with myelofibrosis
19 Aug 2019 //
PHARMABIZ
BMS buoyed by FDA approval of Celgene’s myelofibrosis drug
19 Aug 2019 //
PMLIVE
Celgene notches FDA approval for its `Big 5` JAK inhibitor Inre
17 Aug 2019 //
FIERCE PHARMA
Meet the protein responsible for nearly $100B in cancer drug deals
17 Aug 2019 //
BIOPHARMADIVE
FDA Approves First Myelofibrosis Drug in Nearly a Decade
16 Aug 2019 //
BIOSPACE
UPDATE: Celgene & the scientist who championed fedratinib`s rise Sanofi`s R&D
16 Aug 2019 //
ENDPTS
Celgene wins approval for drug key to Bristol buyout
16 Aug 2019 //
BIOPHARMADIVE
Celgene`s Fedratinib Given Priority Review for Myelofibrosis
05 Mar 2019 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.